OBJECTIVE: To report a series of 11 patients on the severe end of the spectrum of ryanodine receptor 1 (RYR1) gene-related myopathy, in order to expand the clinical, histologic, and genetic heterogeneity associated with this group of patients. METHODS: Eleven patients evaluated in the neonatal period with severe neonatal-onset RYR1-associated myopathy confirmed by genetic testing were ascertained. Clinical features, molecular testing results, muscle imaging, and muscle histology are reviewed. RESULTS: Clinical features associated with the severe neonatal presentation of RYR1-associated myopathy included decreased fetal movement, hypotonia, poor feeding, respiratory involvement, arthrogryposis, and ophthalmoplegia in 3 patients, and femur fractures or hip dislocation at birth. Four patients had dominant RYR1 mutations, and 7 had recessive RYR1 mutations. One patient had a cleft palate, and another a congenital rigid spine phenotype-findings not previously described in the literature in patients with early-onset RYR1 mutations. Six patients who underwent muscle ultrasound showed relative sparing of the rectus femoris muscle. Histologically, all patients with dominant mutations had classic central cores on muscle biopsy. Patients with recessive mutations showed great histologic heterogeneity, including fibrosis, variation in fiber size, skewed fiber typing, very small fibers, and nuclear internalization with or without ill-defined cores. CONCLUSIONS: This series confirms and expands the clinical and histologic variability associated with severe congenital RYR1-associated myopathy. Both dominant and recessive mutations of the RYR1 gene can result in a severe neonatal-onset phenotype, but more clinical and histologic heterogeneity has been seen in those with recessive RYR1 gene mutations. Central cores are not obligatory histologic features in recessive RYR1 mutations. Sparing of the rectus femoris muscle on imaging should prompt evaluation for RYR1-associated myopathy in the appropriate clinical context.
OBJECTIVE: To report a series of 11 patients on the severe end of the spectrum of ryanodine receptor 1 (RYR1) gene-related myopathy, in order to expand the clinical, histologic, and genetic heterogeneity associated with this group of patients. METHODS: Eleven patients evaluated in the neonatal period with severe neonatal-onset RYR1-associated myopathy confirmed by genetic testing were ascertained. Clinical features, molecular testing results, muscle imaging, and muscle histology are reviewed. RESULTS: Clinical features associated with the severe neonatal presentation of RYR1-associated myopathy included decreased fetal movement, hypotonia, poor feeding, respiratory involvement, arthrogryposis, and ophthalmoplegia in 3 patients, and femur fractures or hip dislocation at birth. Four patients had dominant RYR1 mutations, and 7 had recessive RYR1 mutations. One patient had a cleft palate, and another a congenital rigid spine phenotype-findings not previously described in the literature in patients with early-onset RYR1 mutations. Six patients who underwent muscle ultrasound showed relative sparing of the rectus femoris muscle. Histologically, all patients with dominant mutations had classic central cores on muscle biopsy. Patients with recessive mutations showed great histologic heterogeneity, including fibrosis, variation in fiber size, skewed fiber typing, very small fibers, and nuclear internalization with or without ill-defined cores. CONCLUSIONS: This series confirms and expands the clinical and histologic variability associated with severe congenital RYR1-associated myopathy. Both dominant and recessive mutations of the RYR1 gene can result in a severe neonatal-onset phenotype, but more clinical and histologic heterogeneity has been seen in those with recessive RYR1 gene mutations. Central cores are not obligatory histologic features in recessive RYR1 mutations. Sparing of the rectus femoris muscle on imaging should prompt evaluation for RYR1-associated myopathy in the appropriate clinical context.
Authors: C A Sewry; C Müller; M Davis; J S M Dwyer; J Dove; G Evans; R Schröder; D Fürst; T Helliwell; N Laing; R C M Quinlivan Journal: Neuromuscul Disord Date: 2002-12 Impact factor: 4.296
Authors: H Jungbluth; H Zhou; L Hartley; B Halliger-Keller; S Messina; C Longman; M Brockington; S A Robb; V Straub; T Voit; M Swash; A Ferreiro; G Bydder; C A Sewry; C Müller; F Muntoni Journal: Neurology Date: 2005-12-27 Impact factor: 9.910
Authors: H Jungbluth; C R Müller; B Halliger-Keller; M Brockington; S C Brown; L Feng; A Chattopadhyay; E Mercuri; A Y Manzur; A Ferreiro; N G Laing; M R Davis; H P Roper; V Dubowitz; G Bydder; C A Sewry; F Muntoni Journal: Neurology Date: 2002-07-23 Impact factor: 9.910
Authors: M Davis; R Brown; A Dickson; H Horton; D James; N Laing; R Marston; M Norgate; D Perlman; N Pollock; K Stowell Journal: Br J Anaesth Date: 2002-04 Impact factor: 9.166
Authors: Gina Ravenscroft; Joshua S Clayton; Fathimath Faiz; Padma Sivadorai; Di Milnes; Rob Cincotta; Phillip Moon; Ben Kamien; Matthew Edwards; Martin Delatycki; Phillipa J Lamont; Sophelia Hs Chan; Alison Colley; Alan Ma; Felicity Collins; Lucinda Hennington; Teresa Zhao; George McGillivray; Sondhya Ghedia; Katherine Chao; Anne O'Donnell-Luria; Nigel G Laing; Mark R Davis Journal: J Med Genet Date: 2020-10-15 Impact factor: 6.318
Authors: Zhiguang Yuchi; Siobhan M Wong King Yuen; Kelvin Lau; Ainsley Q Underhill; Razvan L Cornea; James D Fessenden; Filip Van Petegem Journal: Nat Commun Date: 2015-08-06 Impact factor: 14.919